Cytotoxic and Antitumor Activities of Doxorubicin Conjugates with the Epidermal Growth Factor and its Receptor-binding Fragment

Author： Lutsenko S.V.   Feldman N.B.   Severin S.E.  

Publisher： Informa Healthcare

ISSN： 1061-186X

Source： Journal of Drug Targeting, Vol.10, Iss.7, 2002-01, pp. : 567-571

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cancer therapies targeted to the epidermal growth factor receptor and its family members

By Kane Susan E  

Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 2, 2006-02 ,pp. : 147-164

Informa Healthcare

Access to resources Recommend Favorite

Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells

By Liu Chia Wen   Lin Wen Jen  

Journal of Drug Targeting, Vol. 21, Iss. 8, 2013-09 ,pp. : 776-786

Informa Healthcare

Access to resources Recommend Favorite

Monoclonal Antibodies Targeting the Epidermal Growth Factor Receptor

By  

Current Drug Targets, Vol. 6, Iss. 3, 2005-05 ,pp. : 275-287

Bentham Science Publishers

Access to resources Recommend Favorite

Epidermal Growth Factor Receptor (EGFR) and its Cross-Talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs

By  

Current Pharmaceutical Design, Vol. 22, Iss. 21, 2016-06 ,pp. : 3226-3236

Bentham Science Publishers

Access to resources Recommend Favorite

Structural Elucidation of Unique Inhibitory Activities of Two Thiazolo[ 4,5-d]pyrimidines Against Epidermal Growth Factor Receptor (EGFR): Implications for Successful Drug Design

By  

Medicinal Chemistry, Vol. 10, Iss. 1, 2014-01 ,pp. : 46-58

Bentham Science Publishers

Access to resources Recommend Favorite